Applications of 2-Bromobutyric Acid in Industrial Manufacturing

2-Bromobutyric acid supports advanced synthesis in chemical plants, pharmaceuticals, agrochemicals, and specialty materials. Its reactive alkyl halide structure enables complex downstream manufacturing routes benefitting from controlled halogenation, chiral intermediates, and specific molecular arrangements.

1. Pharmaceutical Intermediate Synthesis

Pharmaceutical manufacturers employ 2-bromobutyric acid as a key intermediate for the synthesis of active pharmaceutical ingredients, particularly in the production of anticonvulsants, antihypertensives, and specialty beta-blockers. Its chiral center facilitates enantioselective synthesis crucial for consistent therapeutic results. Process chemists leverage it during early-step alkylation or homologation reactions, ensuring high yields and precise stereochemistry before further purification, conversion, or coupling stages.

Industry compliance standards

• ICH Q7 GMP for Active Pharmaceutical Ingredients
• USP/NF Monographs (where applicable for intermediates)
• European Pharmacopoeia directives for pharmaceutical synthesis
• FDA cGMP 21 CFR Part 210/211

Typical usage ratio

• Input ranges from 1.0 to 3.5 molar equivalents per target API intermediate, dependent on downstream coupling route and target active structure requirements; process development teams optimize ratios to minimize impurities and control side reactions.

Downstream process integration

• Introduced in initial or secondary reaction steps, often as an alkyl halide donor or resolving agent; reactors run at moderate temperature (25°C–80°C), followed by selective deprotection, crystallization, or further functional group transformation in multi-step synthesis.

Final product types

• Chiral pharmaceutical actives such as beta-blockers (e.g., phenylethanolamine derivatives)
• Antiepileptic drug intermediates
• Cardiovascular API building blocks
• Custom contract-manufactured molecules for clinical studies

2. Agrochemical Active Ingredient Production

Crop protection manufacturers use 2-bromobutyric acid for chlorinated and brominated intermediates critical in fungicide and herbicide actives. Its structure enables precise introduction of bromine functionality, improving pesticidal selectivity and bioavailability. Production plants integrate it in batch or semi-continuous flow systems, subject to rigorous impurity and residue control due to environmental and food safety regulations.

Industry compliance standards

• FAO/WHO pesticide technical guidelines
• REACH (EC No. 1907/2006) for registration of raw materials
• GLP (OECD) for product development and assessment
• ISO 9001 certified quality management systems for agrochemical production

Typical usage ratio

• 0.8 to 2.2 mole equivalents per agrochemical intermediate, calculated based on targeted halogen substitution level and desired activity spectrum; formulation chemists fine-tune feedstock input to balance cost efficiency and regulatory compliance.

Downstream process integration

• Fed into the alkylation or halogen exchange stage under controlled pH and temperature conditions; product undergoes purification and further derivatization prior to granulation, emulsification, or microencapsulation for finished goods.

Final product types

• Selective herbicide actives (pre-emergent and post-emergent)
• Broad-spectrum fungicide intermediates
• Soil fumigant formulations
• Seed treatment agent components

3. Chiral Compound Manufacturing for Fine Chemicals

Chemical process industries leverage 2-bromobutyric acid for chiral pool synthesis, producing optically pure compounds essential in asymmetric catalysis, specialty polymers, and advanced material coatings. It serves as a building block in catalytic enantioselective reactions and allows precise control over stereochemical purity. Quality control teams monitor residual bromide and byproduct levels to comply with customer specifications in specialty sectors.

Industry compliance standards

• ISO 9001:2015 for custom chemical manufacturing
• ISO 14001:2015 for environmental handling and disposal
• Customer-agreed technical specifications and purity standards (e.g., chiral GC/HPLC analysis, >99% ee requirements)
• Responsible Care® chemical stewardship code

Typical usage ratio

• 0.95 to 1.5 equivalents relative to chiral catalyst or target structure, modified according to desired configuration (R or S) and route-specific conversion yields; process engineers validate input during pilot production scale-up.

Downstream process integration

• Supplied to chiral alkylation or staged catalytic assembly in batch or continuous reactors; intermediate isolates undergo optical purity verification, distillation, or column chromatography before downstream coupling or polymerization.

Final product types

• Enantiomerically pure fine chemicals
• Specialty polymer precursors
• Advanced functional coatings, adhesives, or surface-active agents
• Building blocks for asymmetric organocatalysts

4. API Impurity Profile Control in Custom Synthesis

CDMO (Contract Development and Manufacturing Organization) operations deploy 2-bromobutyric acid to control impurity formation during small-molecule API manufacturing. It serves as a controlled side-chain source for managing metabolite pathways and minimizing unwanted byproducts in multi-step processes under ICH regulatory scrutiny. Analytical labs apply QbD (Quality by Design) principles, tightly tracking input batch purity and integration points.

Industry compliance standards

• ICH Q3A/B for impurities in new drug substances and products
• FDA/EMA harmonized impurity guidelines
• GMP annexes specific to impurity control and risk management, including Annex 8 (Sampling) and Annex 15 (Qualification and Validation)
• Pharmacopoeial requirements for impurity data (USP, EP)

Typical usage ratio

• Varies from 0.1 to 1.0 equivalent relative to target intermediate; determined by risk assessment and real-time impurity monitoring during scale-up or validation stages; adjusted based on route-specific impurity risk and customer tolerance.

Downstream process integration

• Dosed during late-stage synthesis steps where impurity minimization is critical; monitored using in-process HPLC and mass spectrometry; downstream purification cascades include high-resolution distillation, adsorption, or custom crystallization protocols.

Final product types

• GMP-compliant small molecule APIs with documented impurity thresholds
• Clinical trial-grade drug substance lots
• Reference standards for regulatory submissions
• Custom purified intermediates for niche APIs

5. Analytical Reference Standard Production

Specialized analytical labs and reagent manufacturers obtain 2-bromobutyric acid to prepare certified reference materials for chromatographic and spectrometric calibration. This ensures reliable detection and measurement in environmental, pharmaceutical, or toxicological analysis. Accuracy in the synthesis route, including purification and traceability, remains critical to accreditation and usage in regulated laboratories.

Industry compliance standards

• ISO/IEC 17025 for calibration laboratory competence
• ISO 17034 General requirements for reference material producers
• USP <561> for reference standard documentation
• EPA and ECHA guidelines on analytical toxicology standards

Typical usage ratio

• Manufacturers prepare at ≥99.5% chemical purity, dosed in microgram to milligram scale per reference lot; solution concentrations range from 1 μg/mL to 1 mg/mL, aligned with analytical methodology and detection limits.

Downstream process integration

• Fed into small-scale, ultra-high purity synthesis and purification tracks; quality control includes full NMR, IR, and MS characterization before aliquoting and bottling for certified reference distribution.

Final product types

• Certified chromatographic reference standards (GC, HPLC, LC-MS)
• Calibration solutions for regulatory environmental testing
• Pharmaceutical and forensic analytical controls
• Isotope labeling precursors for advanced trace analysis